Literature DB >> 33130306

Xenogeneic-free generation of vascular smooth muscle cells from human induced pluripotent stem cells for vascular tissue engineering.

Jiesi Luo1, Yuyao Lin2, Xiangyu Shi3, Guangxin Li4, Mehmet H Kural5, Christopher W Anderson6, Matthew W Ellis7, Muhammad Riaz1, George Tellides8, Laura E Niklason9, Yibing Qyang10.   

Abstract

Development of mechanically advanced tissue-engineered vascular grafts (TEVGs) from human induced pluripotent stem cell (hiPSC)-derived vascular smooth muscle cells (hiPSC-VSMCs) offers an innovative approach to replace or bypass diseased blood vessels. To move current hiPSC-TEVGs toward clinical application, it is essential to obtain hiPSC-VSMC-derived tissues under xenogeneic-free conditions, meaning without the use of any animal-derived reagents. Many approaches in VSMC differentiation of hiPSCs have been reported, although a xenogeneic-free method for generating hiPSC-VSMCs suitable for vascular tissue engineering has yet to be established. Based on our previously established standard method of xenogeneic VSMC differentiation, we have replaced all animal-derived reagents with functional counterparts of human origin and successfully derived functional xenogeneic-free hiPSC-VSMCs (XF-hiPSC-VSMCs). Next, our group developed tissue rings via cellular self-assembly from XF-hiPSC-VSMCs, which exhibited comparable mechanical strength to those developed from xenogeneic hiPSC-VSMCs. Moreover, by seeding XF-hiPSC-VSMCs onto biodegradable polyglycolic acid (PGA) scaffolds, we generated engineered vascular tissues presenting effective collagen deposition which were suitable for implantation into an immunodeficient mice model. In conclusion, our xenogeneic-free conditions for generating hiPSC-VSMCs produce cells with the comparable capacity for vascular tissue engineering as standard xenogeneic protocols, thereby moving the hiPSC-TEVG technology one step closer to safe and efficacious clinical translation.
Copyright © 2020 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Human induced pluripotent stem cells; vascular smooth muscle cells; vascular tissue engineering; xenogeneic-free

Mesh:

Year:  2020        PMID: 33130306      PMCID: PMC8168373          DOI: 10.1016/j.actbio.2020.10.042

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  59 in total

1.  Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility.

Authors:  Huaigeng Xu; Bo Wang; Miyuki Ono; Akihiro Kagita; Kaho Fujii; Noriko Sasakawa; Tatsuki Ueda; Peter Gee; Misato Nishikawa; Masaki Nomura; Fumiyo Kitaoka; Tomoko Takahashi; Keisuke Okita; Yoshinori Yoshida; Shin Kaneko; Akitsu Hotta
Journal:  Cell Stem Cell       Date:  2019-03-07       Impact factor: 24.633

2.  Tissue engineering of autologous aorta using a new biodegradable polymer.

Authors:  D Shum-Tim; U Stock; J Hrkach; T Shinoka; J Lien; M A Moses; A Stamp; G Taylor; A M Moran; W Landis; R Langer; J P Vacanti; J E Mayer
Journal:  Ann Thorac Surg       Date:  1999-12       Impact factor: 4.330

3.  Direct evidence of endothelial oxidative stress with aging in humans: relation to impaired endothelium-dependent dilation and upregulation of nuclear factor-kappaB.

Authors:  Anthony J Donato; Iratxe Eskurza; Annemarie E Silver; Adam S Levy; Gary L Pierce; Phillip E Gates; Douglas R Seals
Journal:  Circ Res       Date:  2007-05-03       Impact factor: 17.367

4.  Arteriovenous fistulae vs. arteriovenous grafts: a retrospective review of 1,700 consecutive vascular access cases.

Authors:  A F Schild; E Perez; E Gillaspie; C Seaver; J Livingstone; A Thibonnier
Journal:  J Vasc Access       Date:  2008 Oct-Dec       Impact factor: 2.283

5.  Surface hydrolysis of poly(glycolic acid) meshes increases the seeding density of vascular smooth muscle cells.

Authors:  J Gao; L Niklason; R Langer
Journal:  J Biomed Mater Res       Date:  1998-12-05

6.  Functional vascular smooth muscle cells derived from human induced pluripotent stem cells via mesenchymal stem cell intermediates.

Authors:  Vivek K Bajpai; Panagiotis Mistriotis; Yuin-Han Loh; George Q Daley; Stelios T Andreadis
Journal:  Cardiovasc Res       Date:  2012-08-31       Impact factor: 10.787

7.  A highly efficient method to differentiate smooth muscle cells from human embryonic stem cells.

Authors:  Chang-Qing Xie; Jifeng Zhang; Luis Villacorta; Taixing Cui; Huarong Huang; Y Eugene Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-12       Impact factor: 8.311

8.  Tissue-Engineered Vascular Rings from Human iPSC-Derived Smooth Muscle Cells.

Authors:  Biraja C Dash; Karen Levi; Jonas Schwan; Jiesi Luo; Oscar Bartulos; Hongwei Wu; Caihong Qiu; Ting Yi; Yongming Ren; Stuart Campbell; Marsha W Rolle; Yibing Qyang
Journal:  Stem Cell Reports       Date:  2016-07-12       Impact factor: 7.765

9.  iPSC-Derived Endothelial Cells Affect Vascular Function in a Tissue-Engineered Blood Vessel Model of Hutchinson-Gilford Progeria Syndrome.

Authors:  Leigh Atchison; Nadia O Abutaleb; Elizabeth Snyder-Mounts; Yantenew Gete; Alim Ladha; Thomas Ribar; Kan Cao; George A Truskey
Journal:  Stem Cell Reports       Date:  2020-02-06       Impact factor: 7.765

10.  Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells.

Authors:  Christoph Patsch; Ludivine Challet-Meylan; Eva C Thoma; Eduard Urich; Tobias Heckel; John F O'Sullivan; Stephanie J Grainger; Friedrich G Kapp; Lin Sun; Klaus Christensen; Yulei Xia; Mary H C Florido; Wei He; Wei Pan; Michael Prummer; Curtis R Warren; Roland Jakob-Roetne; Ulrich Certa; Ravi Jagasia; Per-Ola Freskgård; Isaac Adatto; Dorothee Kling; Paul Huang; Leonard I Zon; Elliot L Chaikof; Robert E Gerszten; Martin Graf; Roberto Iacone; Chad A Cowan
Journal:  Nat Cell Biol       Date:  2015-07-27       Impact factor: 28.824

View more
  2 in total

Review 1.  Human Induced Pluripotent Stem Cell-Derived Vascular Cells: Recent Progress and Future Directions.

Authors:  Jee Eun Oh; Cholomi Jung; Young-Sup Yoon
Journal:  J Cardiovasc Dev Dis       Date:  2021-11-04

2.  ReMeDy: a platform for integrating and sharing published stem cell research data with a focus on iPSC trials.

Authors:  Kirill Borziak; Irena Parvanova; Joseph Finkelstein
Journal:  Database (Oxford)       Date:  2021-06-22       Impact factor: 4.462

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.